These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19519501)

  • 21. Clinical and electrophysiological evaluation of patients with thalidomide-induced neuropathy.
    Kocer B; Sucak G; Kuruoglu R; Aki Z; Haznedar R; Erdogmus NI
    Acta Neurol Belg; 2009 Jun; 109(2):120-6. PubMed ID: 19681443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Childhood thalidomide neuropathy: a clinical and neurophysiologic study.
    Priolo T; Lamba LD; Giribaldi G; De Negri E; Grosso P; De Grandis E; Veneselli E; Buoncompagni A; Viola S; Alpigiani MG; Gandullia P; Calevo MG
    Pediatr Neurol; 2008 Mar; 38(3):196-9. PubMed ID: 18279755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Potential side effects of thalidomide].
    Rev Prat; 2006 Jan; 56(1):52. PubMed ID: 16548249
    [No Abstract]   [Full Text] [Related]  

  • 24. Thalidomide-induced phrenic nerve paralysis.
    Eswedi A; Burnside P; Morris TC
    Leuk Lymphoma; 2010 Feb; 51(2):342-4. PubMed ID: 20038224
    [No Abstract]   [Full Text] [Related]  

  • 25. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
    Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
    J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in understanding drug-induced neuropathies.
    Peltier AC; Russell JW
    Drug Saf; 2006; 29(1):23-30. PubMed ID: 16454532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal Patterns of Thalidomide Neuropathy in Children and Adolescents.
    Liew WK; Pacak CA; Visyak N; Darras BT; Bousvaros A; Kang PB
    J Pediatr; 2016 Nov; 178():227-232. PubMed ID: 27567409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide in 42 patients with prurigo nodularis Hyde.
    Andersen TP; Fogh K
    Dermatology; 2011; 223(2):107-12. PubMed ID: 21952556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
    Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
    Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances in analytical determination of thalidomide and its metabolites.
    Bosch ME; Sánchez AJ; Rojas FS; Ojeda CB
    J Pharm Biomed Anal; 2008 Jan; 46(1):9-17. PubMed ID: 18023317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.
    Beijers AJ; Oerlemans S; Mols F; Eurelings M; Minnema MC; Vreugdenhil A; van de Poll-Franse LV
    Ann Hematol; 2017 Apr; 96(4):653-663. PubMed ID: 28116479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide, peripheral neuropathy and AIDS.
    Fuller GN; Jacobs JM; Guiloff RJ
    Int J STD AIDS; 1991; 2(5):369-70. PubMed ID: 1659915
    [No Abstract]   [Full Text] [Related]  

  • 34. Palliative oncology: thalidomide.
    Prommer EE
    Am J Hosp Palliat Care; 2010 May; 27(3):198-204. PubMed ID: 19843880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapeutic and antitumour potential of thalidomide analogues.
    Marriott JB; Muller G; Stirling D; Dalgleish AG
    Expert Opin Biol Ther; 2001 Jul; 1(4):675-82. PubMed ID: 11727503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide-induced neuropathy and genetic differences in drug metabolism.
    Harland CC; Steventon GB; Marsden JR
    Eur J Clin Pharmacol; 1995; 49(1-2):1-6. PubMed ID: 8751013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide and cancer.
    McBride W
    Med J Aust; 2002 Sep; 177(5):278. PubMed ID: 12197830
    [No Abstract]   [Full Text] [Related]  

  • 39. Thalidomide in ankylosing spondylitis.
    Huang F; Wei JC; Breban M
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S158-61. PubMed ID: 12463469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enantioselective inhibition of TNF-alpha release by thalidomide and thalidomide-analogues.
    Wnendt S; Finkam M; Winter W; Ossig J; Raabe G; Zwingenberger K
    Chirality; 1996; 8(5):390-6. PubMed ID: 8900028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.